Alligator Bioscience and ImmuRx Enter Into Strategic Collaboration

Swedish Alligator Biosciences AB, which develops protein drug candidates, has entered into a strategic collaboration with American biopharmaceutical company Immurx. The latter is developing an adjuvant platform that stimulates the immune system to fight cancers and chronic infections. The companies will cooperate in the development of a cancer vaccine adjuvant, using their proprietary technology platforms.

For further information please contact:

Gun-Britt Fransson

CEO

Tel:: +46 46 286 4284

Email: guf@alligatorbioscience.com

Or visit: www.alligatorbioscience.com

Home > News & Events > News > Alligator Bioscience and ImmuRx Enter Into Strategic Collaboration
Last updated: 2008-02-29

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

Alligator Bioscience AB

Alligator Bioscience AB

Alligator Bioscience AB is a biotechnology company that focuses on discovery and development of early protein drug candidates, independently and in partnership, within inflammation and cancer. Since 2001, the FIND® (Fragment INduced Diversity) technology platform has been validated by successfully...